Matinas BioPharma reported a net loss attributable to common shareholders of $5.2 million, or a net loss per share of $0.03 for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities were approximately $71.2 million as of March 31, 2020, sufficient to fund operations into the first half of 2023.